N/A
N=11,902
The TackSHS Survey: a Pan-European Study on SHS
Second Hand Tobacco Smoke
Bottom Line
View on ClinicalTrials.gov: NCT02928536 ↗Enrolled (actual)
11,902
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings — 2888 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- no intervention (Other)
- Age
- Pediatric, Adult, Older Adult · 15+ yrs
- Sex
- All
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Primary completion
- Oct 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings |
2888 | — |
| PRIMARY Prevalence of Exposure to Secondhand Aerosol (SHA) From Electronic Cigarettes |
1858 | — |
| SECONDARY Prevalence of Never, Current and Former Smokers |
6513; 2049; 3340 | — |
| SECONDARY Prevalence of Never, Current and Former Electronic Cigarette Users |
11299; 305; 272 | — |
Summary
Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a European cross-sectional study, aiming at i) estimating prevalence and investigating determinants of smoking, e-cigarette use and exposure to SHS and to e-cigarette aerosol; ii) analyzing the attitudes, perceptions and behaviours of the adult European population towards policies to limit SHS exposure; iii) comparing selected smoking-related data between TackSHS and a previously conducted pan-European survey; iv) assessing mortality and morbidity from selected respiratory and cardiovascular diseases attributable to SHS exposure among adults and children in Europe; v) quantifying the economic burden associated to the exposure to SHS and e-cigarette aerosol in Europe. Overall, approximately 12,000 individuals aged 15 years or over will be enrolled in 12 different European countries (BG, DE, ES, FR, GR, IE, IT, LV, PL, PT, RO, UK). Surveys will be representative of the country-specific population in terms of sex, age, and socio-economic characteristics.
Eligibility Criteria
Inclusion Criteria
- individuals aged 15 years and over;
- individuals resident of the 12 selected countries;
- individuals able to understand and answer the questions of the questionnaire of the study in the country-specific language;
- individuals who formally accept to participate in the study.
Exclusion Criteria
No specific exclusion criteria are considered.
Data sourced from ClinicalTrials.gov (NCT02928536). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.